Welcome to our dedicated page for Genetron Holdings news (Ticker: GTH), a resource for investors and traders seeking the latest updates and insights on Genetron Holdings stock.
Genetron Holdings Limited (NASDAQ: GTH) is a leading precision oncology platform company based in China. With a focus on cancer molecular profiling, Genetron leverages advanced technologies in molecular biology and data science to revolutionize cancer treatment.
The company's extensive portfolio spans various stages of cancer management, including early screening, diagnosis, treatment recommendations, and continuous monitoring. Some of its flagship services and products include:
- HCCscreen: A proprietary assay for the early detection of liver cancer.
- 8-gene Lung Cancer Assay: An in-vitro diagnostic tool based on semiconductor sequencing for lung cancer detection.
- Genetron 3D Biochip Reading Instrument and Genetron S5 and S2000: Advanced sequencers for gene detection and panel sequencing.
- IDH1/TERT Gene Assays: Diagnostic assays for glioma.
In addition, Genetron has developed a ctDNA Lung Cancer Assay targeting mutations in the epidermal growth factor receptor gene. The company collaborates with global biopharmaceutical firms to offer tailored genomics research and clinical development services.
Recently, Genetron announced a definitive Agreement and Plan of Merger with New Genetron Holding Limited and Genetron New Co Limited. As part of the merger, Genetron will become a wholly-owned subsidiary of the parent company in a transaction valued at approximately US$126.0 million. This merger signifies a pivotal transformation, taking the company private and enhancing its strategic flexibility.
The merger completion, expected in the first quarter of 2024, is subject to customary closing conditions, including shareholder votes and regulatory approvals. Upon completion, Genetron's American Depositary Shares (ADSs) will be delisted from the Nasdaq Global Market, and the company will terminate its ADS program. The company aims to finalise this transition efficiently to focus on its long-term vision and goals.
For the latest updates and detailed information on Genetron Holdings Limited and its innovative contributions to precision oncology, please visit their Investor Relations page.
Genetron Holdings Limited (Nasdaq: GTH) and CStone Pharmaceuticals have launched a multi-center clinical trial in China to develop a companion diagnostic (CDx) test for avapritinib, a kinase inhibitor targeting the PDGFRA D842V mutation in gastrointestinal stromal tumors (GIST). This CDx test, validated by China's NMPA, is crucial for avapritinib's future approval, which has already received priority review in China. Preliminary Phase I/II data indicates a 62.5% overall response rate in patients treated with avapritinib, marking a significant step in advancing precision medicine for GIST.
Genetron Holdings Limited (GTH) announced participation in the ESMO Virtual Congress 2020, showcasing 18 studies on precision oncology diagnostics and bioinformatics. Key findings include six studies on genetic mutations in the Chinese population, two on immunotherapy biomarkers, and discoveries of tumor-specific genetic variations. The research aims to enhance understanding of cancer treatment, particularly for lung and gastrointestinal cancers. The Company's broad research capabilities position it strongly in the oncology sector, focusing on Chinese population genetics and optimizing bioinformatics for improved cancer diagnostics.
Genetron Holdings Limited (GTH) has formed a strategic partnership with dMed Biopharmaceutical to enhance drug R&D services in oncology. This collaboration combines Genetron's expertise in precision oncology with dMed's strengths in clinical operations and regulatory affairs. The partnership aims to expedite drug development processes for biopharmaceutical companies in China and the U.S. Genetron Health has received seven IVD product approvals, with more in progress. Both firms aspire to boost clinical R&D efficiency and ultimately improve patient outcomes.
Genetron Holdings Limited (NASDAQ: GTH), a leader in precision oncology in China, announced upcoming management participation in two major conferences. The ICBCI International ADR New Economy Conference will take place from September 15-18, 2020, with virtual meetings available on September 15. Additionally, the SVB Leerink CyberRx Series: Oncology Dx and Liquid Biopsy Summit is scheduled for October 6, 2020, featuring a virtual fireside chat at 9:00 am ET.
Genetron Holdings Limited (Nasdaq: GTH) has announced its participation in a significant national research project in China for early screening of lung and digestive system cancers, led by the Ministry of Science and Technology. The project aims to develop a liquid biopsy-based early detection technology platform, targeting 120,000 high-risk lung cancer individuals and over 100,000 patients for digestive cancers. The collaboration includes notable institutions such as the National Cancer Center and the Cancer Hospital, CAMS, highlighting Genetron's role in advancing early cancer detection technology.
Genetron Holdings Limited (GTH) reported its second-quarter 2020 unaudited financial results, showing a 40.3% increase in total revenue to RMB101.7 million compared to Q2 2019. Diagnosis and monitoring revenue rose 52.1% to RMB93.9 million. Gross margin improved to 63.1%, a significant rise from 47.8% in 2019. The net loss widened to RMB2,832.4 million amid substantial fair value losses on financial instruments. The company remains optimistic about its business outlook, intending to expand its product portfolio despite ongoing challenges from COVID-19.
Genetron Holdings Limited (NASDAQ:GTH) announced participation in the Canaccord Genuity 40th Annual Growth Conference, scheduled virtually from August 11-13, 2020. On August 13, management will conduct a fireside chat at 8:00 am ET and a panel discussion at 11:00 am ET focused on cancer screening technologies. The event will be accessible via webcast, with recordings available for 30 days afterward. Genetron is a leading precision oncology platform in China, specializing in molecular profiling tests for cancer management.
Genetron Holdings Limited (NASDAQ:GTH) announced it will release its second quarter financial results for the period ending June 30, 2020, on August 6, 2020, before the US market opens. A conference call for investors will follow at 8:30 a.m. ET, providing details on the Company's performance in precision oncology and molecular profiling tests. The Company leverages advanced technologies in molecular biology and data science for cancer management. Interested parties can access the call and its replay via specified numbers and the Company’s investor relations website.
Genetron Holdings Limited (Nasdaq: GTH) presented findings from 14 clinical studies at the AACR Virtual Annual Meeting on June 22-24, 2020. The studies showcased advancements in Genetron's next-generation sequencing (NGS) technologies, particularly in cancer genetic alteration detection. The One-Step Seq™ Method simplifies library construction, reducing time and costs for hospitals. Innovative approaches to gene fusion detection and liquid biopsy technologies were also highlighted, demonstrating significant sensitivity and specificity. These advancements may enhance cancer diagnosis and treatment, impacting clinical practices positively.
Genetron Holdings Limited has priced its initial public offering (IPO) of 16 million American Depositary Shares (ADSs) at $16.00 each, aiming for gross proceeds of $256 million. The ADSs are set to trade on the Nasdaq Global Market under the symbol GTH starting June 19, 2020. An over-allotment option allows underwriters to purchase up to an additional 2.4 million ADSs, potentially raising an additional $38.4 million. Credit Suisse and China International Capital Corporation are the lead underwriters for this offering.
FAQ
What is the market cap of Genetron Holdings (GTH)?
What does Genetron Holdings Limited specialize in?
What are some of Genetron's key products?
What recent corporate action has Genetron announced?
What is HCCscreen?
What is the significance of Genetron's merger?
What happens to Genetron's ADSs after the merger?
Who are the major stakeholders involved in the merger?
When is the merger expected to complete?
What services does Genetron offer in genomics research?
Where can I find more information about Genetron's financial filings?
